TerrAscend (TSNDF) Cash from Investing Activities (2021 - 2026)
TerrAscend (TSNDF) posted quarterly Cash from Investing Activities of $4000.0 for Q1 2026, up 100.14% year-over-year from $1998.6 in Q1 2025, and up 100.35% quarter-over-quarter from -$1.1 million in Q4 2025.
TerrAscend (TSNDF) Cash from Investing Activities (2021 - 2026) Analysis & Trends
TerrAscend (TSNDF) has reported Cash from Investing Activities for 6 consecutive years, with $4000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Investing Activities rose 100.14% year-over-year to $4000.0; the TTM figure through Mar 2026 stood at -$11.6 million (up 1.13% YoY), while the FY2025 annual figure was -$14.6 million, down 19.27% from the prior year.
- Cash from Investing Activities climbed to $4000.0 in Q1 2026 per TSNDF's latest filing, from -$1.1 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $13.9 million in Q1 2022 and bottomed at -$22.7 million in Q3 2023.
- Historically, Cash from Investing Activities has averaged -$4.8 million across 5 years, with a median of -$3.1 million in 2025.
- Annual changes were most pronounced in 2022 — Cash from Investing Activities soared 207.98% — and 2024, when it sank 605.09%.
- TerrAscend's Cash from Investing Activities stood at -$15.0 million in 2022, then soared by 108.25% to $1.2 million in 2023, then tumbled by 605.09% to -$6.2 million in 2024, then jumped by 81.71% to -$1.1 million in 2025, then jumped by 100.35% to $4000.0 in 2026.
- Business Quant data shows TSNDF's Cash from Investing Activities at $4000.0 in Q1 2026, -$1.1 million in Q4 2025, and -$3.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -491.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | -300.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -550.24 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 87.50 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -51.60 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | -135.40 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | -110.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | TerrAscend | 182.53 Mn | 140.41 Mn | 36.25 Mn | -1.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.83 Mn |
| Jun 30, 2026 | -1.83 Mn |
| Mar 31, 2026 | 4,000.00 |
| Mar 31, 2026 | 4,000.00 |
| Dec 31, 2025 | -1.14 Mn |
| Dec 31, 2025 | -1.14 Mn |
| Sep 30, 2025 | -3.08 Mn |
| Sep 30, 2025 | -3.08 Mn |
| Jun 30, 2025 | -7.43 Mn |
| Jun 30, 2025 | -7.43 Mn |
| Mar 31, 2025 | -2.96 Mn |
| Mar 31, 2025 | -2.96 Mn |
| Dec 31, 2024 | -6.25 Mn |
| Dec 31, 2024 | -6.25 Mn |
| Sep 30, 2024 | -956,000.00 |
| Sep 30, 2024 | -956,000.00 |
| Jun 30, 2024 | -1.62 Mn |
| Jun 30, 2024 | -1.62 Mn |
| Mar 31, 2024 | -3.42 Mn |
| Mar 31, 2024 | -3.42 Mn |